Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PHVS Pharvaris N.V.

交易中 02-17 09:45:58 EST

26.35

-0.10

-0.38%

最高26.65	最低26.35	成交量1,628
今开26.49	昨收26.45	日振幅1.13%
总市值17.12亿	流通市值8.93亿	总股本6,496万
成交额4.33万	换手率0.00%	流通股本3,391万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":26.35,"timestamp":1771339513562,"preClose":26.45,"halted":0,"volume":1628,"delay":0,"changeRate":-0.0037807183364838514,"floatShares":33905700,"shares":64959500,"eps":-3.402257,"marketStatus":"交易中","change":-0.1,"latestTime":"02-17 09:45:58 EST","open":26.49,"high":26.65,"low":26.35,"amount":43314.730800000005,"amplitude":0.011342,"askPrice":27.4,"askSize":105,"bidPrice":26.35,"bidSize":423,"shortable":3,"etf":0,"ttmEps":-3.402257,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771362000000},"marketStatusCode":2,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":26.45,"postHourTrading":{"tag":"盘后","latestPrice":26.45,"preClose":26.45,"latestTime":"17:21 EST","volume":10222,"amount":270371.9,"timestamp":1771021283762,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.452186,"impliedVol":0.8819,"impliedVolPercentile":0.7564},"requestUrl":"/m/hq/s/PHVS/wiki","defaultTab":"wiki","newsList":[{"id":"2601835331","title":"Pharvaris N.V.盘中异动 早盘快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601835331?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:25","pubTimestamp":1767626746,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日23时25分，Pharvaris N.V.股票出现异动，股价急速跳水5.10%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为1.89%。Pharvaris 利用新型小分子药物直接靶向这一临床治疗靶点，并凭借在 2 期预防和 HAE 研究中取得的积极数据，正在开发 deucrictibant。Pharvaris 目前正在招募一项治疗 HAE 的关键性 3 期试验，并计划启动一项用于预防 HAE 的关键性 3 期 deucrictibant 试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105232546a6f6892d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105232546a6f6892d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2592211790","title":"Pharvaris N.V.盘中异动 临近午盘股价大涨5.10%报25.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592211790","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592211790?lang=zh_cn&edition=full","pubTime":"2025-12-20 00:59","pubTimestamp":1766163568,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日00时59分，Pharvaris N.V.股票出现异动，股价大幅上涨5.10%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.26%。Pharvaris 利用新型小分子药物直接靶向这一临床治疗靶点，并凭借在 2 期预防和 HAE 研究中取得的积极数据，正在开发 deucrictibant。Pharvaris 目前正在招募一项治疗 HAE 的关键性 3 期试验，并计划启动一项用于预防 HAE 的关键性 3 期 deucrictibant 试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220005928a6b7f6c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220005928a6b7f6c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"1126748116","title":"Pharvaris股价在盘前交易中上涨19.6%，因其遗传性血管性水肿治疗的三期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1126748116","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126748116?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:02","pubTimestamp":1764766934,"startTime":"0","endTime":"0","summary":"Pharvaris股价在盘前交易中上涨19.6%，因其遗传性血管性水肿治疗的三期临床试验结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"1162914731","title":"Pharvaris公布Rapide-3关键研究的积极顶线数据，确认Deucrictibant在按需治疗HAE发作中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1162914731","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162914731?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:51","pubTimestamp":1764762669,"startTime":"0","endTime":"0","summary":"Pharvaris公布Rapide-3关键研究的积极顶线数据，确认Deucrictibant在按需治疗HAE（遗传性血管性水肿）发作中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"1107187110","title":"Pharvaris N.V.: 资金充足，助力美国公司度过2027年上半年关键转折点","url":"https://stock-news.laohu8.com/highlight/detail?id=1107187110","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107187110?lang=zh_cn&edition=full","pubTime":"2025-11-12 19:52","pubTimestamp":1762948336,"startTime":"0","endTime":"0","summary":"Pharvaris N.V.: 资金充足，助力美国公司度过2027年上半年关键转折点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2564332946","title":"Pharvaris N.V.盘中异动 早盘快速拉升5.31%报22.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564332946","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564332946?lang=zh_cn&edition=full","pubTime":"2025-09-02 22:29","pubTimestamp":1756823385,"startTime":"0","endTime":"0","summary":"北京时间2025年09月02日22时29分，Pharvaris N.V.股票出现异动，股价大幅上涨5.31%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.41%。Pharvaris 利用新型小分子药物直接靶向这一临床治疗靶点，并凭借在 2 期预防和 HAE 研究中取得的积极数据，正在开发 deucrictibant。Pharvaris 目前正在招募一项治疗 HAE 的关键性 3 期试验，并计划启动一项用于预防 HAE 的关键性 3 期 deucrictibant 试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902222945950ebd2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902222945950ebd2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2518979278","title":"Pharvaris N.V.盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518979278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518979278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613493,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Pharvaris N.V.股票出现波动，股价快速拉升5.26%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.59%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2517600731","title":"Pharvaris N.V.盘中异动 急速跳水5.67%报14.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517600731?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:44","pubTimestamp":1741279483,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时44分，Pharvaris N.V.股票出现波动，股价快速下挫5.67%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.33%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307004444abeb97e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307004444abeb97e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2517928498","title":"Pharvaris N.V.盘中异动 下午盘大幅下挫6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517928498","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517928498?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:38","pubTimestamp":1741199916,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时38分，Pharvaris N.V.股票出现波动，股价大幅跳水6.15%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.43%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306023836963b123e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306023836963b123e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2516363742","title":"Citizens Capital Markets：重申Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由55.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516363742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516363742?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由55.00美元调整至55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PHVS"],"gpt_icon":0},{"id":"2509478557","title":"Pharvaris N.V.盘中异动 股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509478557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509478557?lang=zh_cn&edition=full","pubTime":"2025-02-07 03:54","pubTimestamp":1738871677,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日03时54分，Pharvaris N.V.股票出现波动，股价快速上涨5.19%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.53%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207035439961a47a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207035439961a47a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2508988919","title":"摩根大通证券公司：维持Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由46.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508988919","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508988919?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:13","pubTimestamp":1738343582,"startTime":"0","endTime":"0","summary":"摩根大通证券公司：维持Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由46.00美元调整至55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01011347922518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PHVS","159848","399975"],"gpt_icon":0},{"id":"2506894971","title":"Pharvaris N.V.盘中异动 大幅跳水5.12%报18.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506894971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506894971?lang=zh_cn&edition=full","pubTime":"2025-01-25 02:55","pubTimestamp":1737744922,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日02时55分，Pharvaris N.V.股票出现波动，股价大幅下挫5.12%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.15%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025522960fb70d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025522960fb70d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2505527254","title":"Pharvaris N.V.盘中异动 早盘股价大涨6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505527254","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505527254?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:50","pubTimestamp":1737471048,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时50分，Pharvaris N.V.股票出现异动，股价快速上涨6.21%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.15%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225048a22a5bab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225048a22a5bab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2504195539","title":"Pharvaris N.V.盘中异动 快速上涨5.10%报18.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504195539?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:48","pubTimestamp":1737128887,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时48分，Pharvaris N.V.股票出现异动，股价快速拉升5.10%。截至发稿，该股报18.34美元/股，成交量6325股，换手率0.01%，振幅4.41%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.83%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172348079607aa5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172348079607aa5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2503585586","title":"Pharvaris N.V.盘中异动 早盘股价大跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503585586","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503585586?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:33","pubTimestamp":1736778796,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时33分，Pharvaris N.V.股票出现异动，股价大幅跳水5.73%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.98%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132233169864d617&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132233169864d617&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2502811772","title":"Pharvaris N.V.盘中异动 下午盘急速下跌5.50%报17.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502811772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502811772?lang=zh_cn&edition=full","pubTime":"2025-01-11 04:02","pubTimestamp":1736539349,"startTime":"0","endTime":"0","summary":"北京时间2025年01月11日04时02分，Pharvaris N.V.股票出现异动，股价快速下挫5.50%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为2.21%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011104022995ffaa13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011104022995ffaa13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2501735593","title":"Pharvaris N.V.盘中异动 下午盘急速上涨7.31%报19.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501735593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501735593?lang=zh_cn&edition=full","pubTime":"2025-01-08 02:21","pubTimestamp":1736274094,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日02时21分，Pharvaris N.V.股票出现异动，股价急速拉升7.31%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.31%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108022134aba2101d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108022134aba2101d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2500690642","title":"Pharvaris N.V.盘中异动 股价大跌5.06%报18.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500690642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500690642?lang=zh_cn&edition=full","pubTime":"2025-01-03 03:17","pubTimestamp":1735845426,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日03时17分，Pharvaris N.V.股票出现波动，股价急速下挫5.06%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.26%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010303170698593647&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010303170698593647&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2495752873","title":"Pharvaris N.V.盘中异动 股价大跌6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495752873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495752873?lang=zh_cn&edition=full","pubTime":"2024-12-30 22:35","pubTimestamp":1735569304,"startTime":"0","endTime":"0","summary":"北京时间2024年12月30日22时35分，Pharvaris N.V.股票出现异动，股价快速下跌6.43%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.60%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123022350495f2c386&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123022350495f2c386&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharvaris.com","stockEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.032},{"period":"3month","weight":0.1231},{"period":"6month","weight":0.1861},{"period":"1year","weight":0.5227},{"period":"ytd","weight":-0.0468}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pharvaris N.V.于2015年9月30日注册在荷兰成立。他们是一家临床阶段的生物制药公司，致力于针对尚未满足需求的罕见疾病的创新疗法的开发和商业化，最初的重点是血管性水肿和其他缓激肽介导的疾病。他们的第一个分子PHA121是新型的小分子缓激肽B2受体拮抗剂，可用于治疗遗传性血管性水肿或HAE。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.009318},{"month":2,"riseRate":0,"avgChangeRate":-0.091468},{"month":3,"riseRate":0.4,"avgChangeRate":-0.042615},{"month":4,"riseRate":0.6,"avgChangeRate":0.04111},{"month":5,"riseRate":0.2,"avgChangeRate":-0.101468},{"month":6,"riseRate":0.6,"avgChangeRate":0.189847},{"month":7,"riseRate":0.4,"avgChangeRate":0.02128},{"month":8,"riseRate":0.8,"avgChangeRate":-0.020522},{"month":9,"riseRate":0.6,"avgChangeRate":-0.015739},{"month":10,"riseRate":0.2,"avgChangeRate":-0.072433},{"month":11,"riseRate":0.4,"avgChangeRate":-0.106545},{"month":12,"riseRate":0.4,"avgChangeRate":0.958602}],"exchange":"NASDAQ","name":"Pharvaris N.V.","nameEN":"Pharvaris N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pharvaris N.V.,PHVS,Pharvaris N.V.股票,Pharvaris N.V.股票老虎,Pharvaris N.V.股票老虎国际,Pharvaris N.V.行情,Pharvaris N.V.股票行情,Pharvaris N.V.股价,Pharvaris N.V.股市,Pharvaris N.V.股票价格,Pharvaris N.V.股票交易,Pharvaris N.V.股票购买,Pharvaris N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}